Full-Time

Sales Development Manager - Biotech/Pharma

Zeiss

Zeiss

1,001-5,000 employees

Corporate venture capital for deep-tech startups

Compensation Overview

$110k - $138k/yr

Company Does Not Provide H1B Sponsorship

California, USA + 1 more

More locations: South Dakota, USA

Remote

Remote within California or South Dakota; domestic travel is approximately 60–70% and global travel approximately 10%.

Bachelor's

Category
Sales & Account Management (1)
Biology & Biotech (1)

Get referred to Zeiss

See people who can refer or advise you

Requirements
  • A Bachelor’s degree or higher in Biological Science or related fields.
  • A comprehensive understanding of the biotech and pharmaceutical sector.
  • A minimum of 2 years sales experience and/or experience working within the biotech and pharmaceutical market.
  • A willingness to travel domestically (~70%) and globally (~10%).
  • Strong presentation and interpersonal skills with an ability to communicate confidently, effectively and persuasively.
  • Demonstrated knowledge of microscopy techniques, their applications, and how they are utilized in biotech and pharmaceutical drug discovery and development environments.
  • Capable and willing to engage customers in their workspace/environment, including BSL-2 and BSL-3 facilities.
  • Must have a driving record in good standing, a valid driver license, and be able to drive a company-provided car/van.
  • Must have valid employment authorization to work in the United States.
  • Must have the ability to procure a passport for international travel.
  • Ability to lift microscope equipment to 75 pounds.
Responsibilities
  • Drive new business growth by identifying and developing sales opportunities within the biotech and pharmaceutical sectors.
  • Build strong relationships through in-person visits and networking to generate leads and open new doors with biopharma customers.
  • Explore and develop opportunities for services business and software portfolio sales, including enterprise solutions projects.
  • Organize and lead workshops, webinars, and on-site events including tradeshows to engage customers by delivering presentations that showcase ZEISS solutions to drive sales opportunities.
  • Collaborate with the Business Development Manager Team to develop and execute effective campaigns that complement ongoing digital efforts and directly support sales efforts and opportunity generation.
  • Leverage networks to support the Business Development Manager in creating domain-specific and voice-of-customer content.
  • Establish and nurture partnerships with biopharma organizations to expand ZEISS’s market presence.
  • Provide biotech and pharma industry insights to support the sales team in key opinion leader meetings and help close key opportunities.
  • Stay informed on industry trends and competitor activities to uncover new sales opportunities.
Desired Qualifications
  • Prior experience in the biotech and pharmaceutical sector, or selling to these industries, is highly valuable.

ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$67.7M

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ZEISS led Maculaser's May 2026 round for retinal laser therapy commercialization.
  • ZEISS Ventures led SeeTrue's €2.2 million round on August 6, 2026.
  • ZEISS launched ClearMind lenses and DuraVision Plus in January 2026, reinforcing optical leadership.

What critics are saying

  • Carl Zeiss Meditec cut 2026 revenue 5.7% and targets 1,000 job reductions.
  • ZEISS's 2026 restructuring threatens innovation velocity and employee morale through 2028/29.
  • A prolonged MedTech slump or failed turnaround would weaken ZEISS Ventures' strategic value.

What makes Zeiss unique

  • ZEISS Ventures pairs capital with ZEISS distribution, engineering, and ophthalmology channels.
  • Its 2026 deals target eye health, imaging, and optoelectronics adjacencies.
  • ZEISS brand credibility de-risks pilots for startups selling into regulated healthcare.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Company News

ZEISS
Aug 5th, 2026
ZEISS leads $2.5M investment in SeeTrue Technologies for miniaturised eye-tracking tech

ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.

PR Newswire
Jun 11th, 2026
ZEISS completes early implantations of AT LUCIA toric 721P intraocular lens

ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.

ZEISS
May 28th, 2026
ZEISS invests in Maculaser to advance temperature-controlled retinal laser therapy

ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.

PR Newswire
May 13th, 2026
ZEISS gains COFEPRIS approval for ARTEVO 850 and MICOR 700 ophthalmic surgical systems in Mexico

ZEISS Medical Technology has received approval from Mexico's COFEPRIS for two ophthalmic surgical devices: the ARTEVO 850 microscope and MICOR 700 lens removal device. Both technologies are compatible with ZEISS's latest cataract workflow systems. The ARTEVO 850 is a 3D heads-up ophthalmic microscope offering true colour imaging and a nearly 60% increase in depth of field. The MICOR 700 is the first handheld lens removal device with ultrasound-free operation, using ZEISS's non-ultrasonic lens extraction procedure to minimise risk to surrounding eye structures. The products will be showcased at the Mexican Congress of Ophthalmology in Monterrey from 30 May to 3 June 2026. ZEISS Medical Technology generated revenue of €2,066.1 million in fiscal year 2023/24.

Gridley Herald
Apr 29th, 2026
Hypervision Surgical raises $21.6M Series A for AI-assisted surgery platform

Hypervision Surgical, a UK-based pioneer in real-time hyperspectral imaging for surgery, has raised £17 million in an oversubscribed Series A round led by Heal Capital. Angelini Ventures participated alongside IP Group and Daycrest, with Angelini Ventures Managing Director Tanja Dowe joining the board. The King's College London spin-out has developed the Hyperspectral Intelligence platform, which combines hyperspectral sensing with AI-driven analytics to provide real-time, quantitative insights into tissue physiology during surgery. The technology captures information beyond what conventional surgical cameras can perceive, potentially improving intraoperative decision-making and reducing complications. The funding will support commercial deployment, clinical adoption and development of next-generation hyperspectral sensing technology. The company's HYPERSNAP system is certified in the UK and cleared by the US FDA.